What does it do?
ClearOne is a transition-stage business that currently functions as a shell company following the divestiture of its entire operating business in October 2025. Following the sale of its audio-visual and conferencing assets to Biamp Systems, the company stopped manufacturing and selling products. It currently generates no revenue from operations and exists primarily to manage legacy accounts receivable, technical support for old products, and the completion of its definitive merger agreement with Cortigent, Inc. If the merger closes, the company will rebrand as Cortigent Holdings and operate as a medical technology firm focused on neurostimulation and brain-computer interfaces.
Where does revenue come from?
The company has reported zero revenue from continuing operations since the fourth quarter of 2025. Before the asset sale, revenue came from conferencing, collaboration, and network streaming solutions, but these segments have been classified as discontinued operations. Geographically, the business formerly served a global market, but current financial activity is limited to administrative expenses and the recovery of prepaid assets.
Revenue Breakdown
Revenue by Geography
Who are its customers?
ClearOne has no active customer base following the liquidation of its product inventory and customer data rights to Biamp Systems. Prior to 2026, the company served enterprise clients and AV integrators, but these relationships and the rights to serve them were transferred in the asset sale. The future entity, Cortigent, will eventually serve clinical researchers and healthcare providers, but it currently has no commercial customers as its products are in the clinical and pre-clinical development stages.
What gives it staying power?
The company has virtually no moat or staying power in its current form beyond its remaining cash and its Nasdaq listing status. It is effectively a vehicle for a reverse merger, and its survival depends entirely on the successful acquisition of Cortigent's intellectual property and the ability to raise fresh capital.
Where is it headed?
Management is betting the company's future on the neurotechnology market through the Cortigent acquisition. The strategic goal is to transform from a struggling hardware vendor into a developer of life-altering medical devices like the Orion visual prosthesis. This shift moves the company from the low-margin communication hardware sector into the high-risk, high-reward field of brain-computer interface clinical development.
ClearOne has entered a state of operational dormancy with zero revenue following the total divestiture of its core business assets in late 2025. The 2025 fiscal year ended with $0 in revenue compared to $10 million in 2024, reflecting the deliberate liquidation of the company's conferencing and collaboration segments. This results in massive technical losses as the company continues to incur public-company compliance and merger-related expenses without any matching income.
Cash flow is currently negative as the company burns through its remaining reserves to fund the transition to its new biotech identity. While the company saw a spike in free cash flow in 2023 due to temporary working capital shifts, it has historically struggled with cash generation and now faces a mandatory $10 million to $15 million financing hurdle to close its pending merger. The lack of operating income makes the company entirely dependent on external capital markets for survival.
The balance sheet is currently clean of debt but lacks the liquidity needed to fund its planned medical technology development. With a debt-to-equity ratio of -1.31 and a net cash position, the company is not burdened by legacy loans, but its existing assets are insufficient to cover the high costs of clinical trials expected post-merger. The company is essentially a cash shell waiting for a recapitalization event.
ClearOne is a financially hollowed-out entity whose historical metrics no longer reflect its future risks or potential. ClearOne is a financially hollowed-out entity whose historical metrics no longer reflect its future risks or potential.
ClearOne does not pay a dividend and has prioritized cash preservation during its total business restructuring. While the company issued a special stock dividend of preferred shares in July 2025, there is no recurring cash yield for common stockholders. The company has not engaged in meaningful share buybacks recently, and the share count is set to explode from 2.6 million to over 15 million shares if the Cortigent merger closes. This planned issuance will dilute existing owners by more than 80%, meaning any future value will be split among a much larger pool of shares.
The company successfully avoided bankruptcy by selling its core assets for cash and finding a merger partner to provide a new business direction. This pivot provides a potential path for shareholders to recover value through a high-growth biotech sector rather than a declining hardware business. The sale to Biamp Systems effectively cleared the legacy liabilities and inventory from the books.
The mandatory $10 million to $15 million financing round is the single most critical trigger for the company's near-term survival. If ClearOne fails to raise this capital on the required terms, the Cortigent merger will likely collapse, leaving the company with no operating business and dwindling cash. This funding risk is exacerbated by the legal investigations currently surrounding the fairness of the merger price.
The neurostimulation and brain-computer interface market is currently estimated at roughly $6 billion globally and is projected to exceed $11 billion by 2030 as clinical trials move toward commercialization. This is an emerging industry where pricing power is high due to life-altering medical benefits, but it is currently a race for FDA approval rather than a battle for market share. ClearOne is attempting to enter this space as a micro-cap challenger through its merger with Cortigent. The growth runway is enormous if the technology works, but the market is currently dominated by massive med-tech incumbents and well-funded private firms like Neuralink.
The neurotechnology market is characterized by high barriers to entry due to intense regulatory scrutiny and the massive capital required for clinical trials. Competition is currently rational, as different firms are targeting various neurological conditions, though the battle for neurosurgeon mindshare and hospital system adoption will eventually become brutal. The clinical stage of most projects means that survival is a more immediate concern than pricing wars.
Neuralink is the most dangerous competitor because its massive funding and public profile allow it to attract top talent and move through clinical phases faster than micro-cap entities. Incumbents like Medtronic and Abbott threaten the space by having the existing distribution networks to bundle new neuro-tech products into their massive healthcare contracts. Smaller firms like Synchron are attacking the market with less invasive surgical techniques that could make Cortigent's implantable solutions look obsolete.
ClearOne currently has zero market share and is under extreme pressure to secure the funding needed to even begin competing.
ClearOne currently possesses no primary source of protection because it has divested all conferencing and audio IP that once formed its identity. Any future moat will depend entirely on the patents and proprietary neurostimulation algorithms held by Cortigent. The current shell entity is completely exposed to any competitor with a functioning product and a sales force.
Financial metrics like the -670.1% ROIC and zero revenue prove that no economic moat exists to protect the business from losses. The margins are non-existent because there is no product to sell, and the net loss reflects the costs of maintaining a public listing for a business in transition. The lack of any commercial activity means there is no barrier preventing a well-funded rival from taking the entire market.
The moat direction is stable at zero, as there is no further business value to lose. The transition to Cortigent will introduce a Narrow moat based on medical patents, but this will remain speculative until the products reach a more advanced clinical stage.
Completed core asset sale in 2025 to Biamp Systems.
FY2025 revenue dropped to $0 following total business divestiture.
Massive 80%+ dilution planned for existing common shareholders.
Capital Allocation Track Record
Derek Graham has managed a difficult liquidation and transition process that successfully avoided immediate insolvency through the sale of the core AV business. While the decision to sell the entire operating unit was a drastic move that left the company with no revenue, it effectively cleared the deck for the Cortigent merger. Management's strategic judgment is now under scrutiny as they attempt a massive pivot into a medical device field where they have no prior experience.
The primary governance risk is the massive dilution facing current shareholders, as the merger will result in Vivani Medical controlling the vast majority of the company. Following the close, the board will be restructured to give Vivani designated directors, effectively turning ClearOne into a subsidiary of its merger partner. Investors are essentially betting on the caliber of the incoming Cortigent leadership team rather than the legacy ClearOne management that oversaw the business liquidation.
Successful Cortigent merger provides entry into high-growth neurotech market. The acquisition of Cortigent's BCI technology gives ClearOne a high-upside pipeline in brain-computer interfaces that could be worth far more than the legacy AV business.
Orion visual prosthesis achieves breakthrough FDA clinical trial results. Positive data from vision-restoration trials would significantly de-risk the new business and likely lead to a major re-rating of the stock.
Successful $15 million financing provides runway for clinical development. Securing the maximum targeted financing would provide the liquidity needed to reach the next set of clinical data readouts.
Failure to secure $10M minimum financing collapses the merger. If the required capital isn't raised, the Cortigent deal fails and ClearOne remains a shell with no operating business.
Clinical trial failures for primary neurostimulation programs. Negative data or safety issues in the Orion or stroke recovery programs would destroy the value of the newly acquired biotech assets.
Massive dilution from share issuance and advisor warrants. Issuing 12.5 million shares to Vivani Medical severely limits the per-share upside for legacy stockholders even if the business succeeds.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We value ClearOne on the small profit it earns as it winds down its old business. Since the company no longer makes or sells products, its only value comes from the cash left on its books and the "lottery ticket" potential of the upcoming merger. A single multiple on next year's sales or cash flows would not work here because the business is changing completely.
Multiplying the expected 2026 profit of 15 cents per share by a 10x multiple gives us a fair value of $1.50. We used 10x, which is lower than typical tech rivals like Agora (currently priced as a platform) because ClearOne has no active operations and is essentially starting from scratch. We deviate from the engine's $0.00 value because the shell structure and the 15-cent profit from the asset sale provide a floor that the long-term model ignores.
Priced on its remaining cash instead, we get a value of roughly $0.65 per share, which is well below our $1.50 estimate. This lower number comes from dividing the $1.75 million the company raised earlier this year by its 2.7 million shares. Since the two values disagree by more than 50%, it shows how much of the current stock price is based on "hope" for the merger rather than what the company actually owns today. We trust the $1.50 number more because it includes the value of the shell's listing on the Nasdaq, which is worth something to the company it is merging with.
The biggest risk is the massive share dilution required to fund the new biotech business. To raise the needed $10 million to $15 million, ClearOne will likely have to issue millions of new shares, which could knock the fair value down from $1.50 toward $0.50 per share for existing owners. Watch the official share count in the first post-merger filing for any jump above 6 million shares.
Bear case ($0): The Cortigent merger fails to close or the mandatory $10 million financing round collapses; or Nasdaq delists the stock before the merger can reset the company's compliance status.
Bull case ($4): The merger closes and Cortigent’s brain-computer interface (Orion) achieves clinical milestones without further dilution; or The company secures more than $15 million in funding at a valuation significantly higher than current levels.
Clearthesis wrote this report from 35 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on September 28, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.